Dr. Tsimberidou is a Professor of Medicine in the Department of Investigational Cancer Therapeutics, and a Katherine Russell Dixie Distinguished Endowed Professor at The University of Texas MD Anderson Cancer Center. She has designed highly innovative clinical trials that have changed the standard of practice of oncology and improved the clinical outcomes of patients with solid tumors and hematologic malignancies. She pioneered the personalized medicine program across tumor types at MD Anderson. In 2007, she developed the IMPACT (Initiative for Personalized Medicine and Advanced Cancer Therapy) program and demonstrated that identifying tumor specific molecular aberrations and selecting therapy based on tumor abnormalities of individual patients with advanced cancer is associated with better overall outcomes compared with standard approaches.

Her research accomplishments have garnered extensive media coverage by ASCO, The Economist, The Wall Street Journal, Bloomberg, and the Boston Globe. She has published over 350 articles in high-impact peer-reviewed journals and book chapters and co-edited major textbooks in oncology. She has been invited to present her work at numerous conferences. She has received prestigious awards and was appointed to serve on several committees at ASCO and the Worldwide Innovative Network (WIN) consortium in Precision Medicine. She is a board member of the Coalition for Personalized Medicine. Dr. Tsimberidou is a Fellow of ASCO (FASCO) and a Fellow of the American Association for the Advancement of Science (AAAS) for “seminal contributions to instantiating and implementing precision oncology through innovative therapeutic approaches, patient care, and education aimed at improving clinical outcomes across tumor types.” 

Disclosure: Dr. Tsimberidou receives compensation as a member of the BrYet scientific advisory board, and this financial relationship has been disclosed to MD Anderson’s Conflict of Interest committee in accordance with institutional policy.